There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative to existing mental health treatments.
UK-based Small Pharma has launched on the Toronto's TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) to develop medicines based on N,N-Dimethyltryptamine (DMT) to tre
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio